Reports and influencing factors of drug-induced hypokalemia induced by diammonium glycyrrhizinate

doi:10.19803/j.1672-8629.2022.05.12

Abstract

Abstract: Objective To analyze reports and influencing factors of drug-induced hypokalemia in diammonium oxalate adverse reactions. Methods the ADR reports from January 1, 2004 to June 30, 2020 of diammonium glycyrrhizinate collected by the national adverse drug reaction monitoring system from January 1, 2004 to June 30, 2020 were retrospectively analyzed. A total of 12 816 adverse reaction/event reports of diammonium glycyrrhizinate were included in the analysis, including 110 reports of hypokalemia. The reporting rate of hypokalemia was analyzed according to age, gender, dosage form, medication time and underlying diseases (diabetes and hypertension). The chi-square test was conducted to compare the difference in the reports rate of hypokalemia among different groups. Logistic regression analysis was conducted to further explore the influencing factors of hypokalemia. Results Among the adverse reactions of diammonium glycyrrhizinate, the reporting rate of hypokalemia was 1.72% in the oral preparation group, and 0.56% in the injection preparation group (the difference was statistically significant) and the reporting rate of hypokalemia increased significantly with age as well as duration of medication. Logistic regression analysis showed that the corrected OR value of the oral preparation was 2.171 compared with the injection preparation. The corrected OR values of middle-aged and elderly groups were 2.534 and 3.394 compared with the young group. The corrected OR values of 2~3, 4~6, 7~14, 15~30 and >; 30 days were 6.761, 28.253, 28.762, 48.071 and 134.501 compared with the 1 day group. The corrected OR value of diabetic patients was 3.223 compared with non-diabetic patients. Conclusion Elderly, oral preparations, long time medication and diabetes mellitus are risk factors for drug-induced hypokalemia among the adverse reaction of diammonium glycyrrhizinate.

Key words: diammonium glycyrrhizinate, adverse drug reaction, hypokalemia, drug origin, logistic regression analysis

CLC Number:

R994.11

WANG Chunting, WEN Wen. Reports and influencing factors of drug-induced hypokalemia induced by diammonium glycyrrhizinate[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 532-536.

References

[1] SHEN XM, WANG WP.Pediatrics(儿科学)[M]. 7th ed. Beijing: People's Medical Publishing House, 2011: 3.
[2] National Center for ADR Monitoring. WHO adverse reaction terminology(WHO药品不良反应术语集)[M]. Beijing: China Medical Science and Technology Press, 2003.
[3] ZHANG LL, SONG HT.Retrospective analysis on 328 adverse drug reaction reports from department of pediatrics in a grade 3 and first-class hospital from 2013 to 2017[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2019, 16(1): 32-35.
[4] PAN WW, NI SQ, LI CM, et al.A survey of public perception on clinical research in children[J]. Chinese Journal of Hospital Administration(中华医院管理杂志), 2017, 33(1): 75-78.
[5] XIA MQ, BI J, ZHANG YF.Pharmaceutical care for one pediatric patient with drug hypersensitivity syndrome[J]. Journal of Pediatric Pharmacy(儿科药学杂志), 2018, 24(7): 39-42.
[6] LIU C, XU HM, TAN LP, et al.Clinical analysis of drug hypersen-sitivity syndrome in 22 children[J]. J Clin Pediatric(临床儿科杂志), 2017, 35(7): 522-524.
[7] KAMIJIMA M, WANG H, YAMANOSHITA O, et al.Occupational trichlor-oethylene hypersensitivity syndrome: human herpesvirus 6 reactivation and rash phenotypes[J]. J Dermatol Sci, 2013, 72(3): 218-224.
[8] UNO H, KABASHIMA K, TOHYAMA M, et al.TNF-α as a useful predictor of human herpesvirus-6 reactivation and indicator of the disease process in drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS)[J]. J Dermatol Sci, 2014, 74(2): 177-179.
[9] OGAWA K, MORITO H, HASEGAWA A, et al.Elevated serum thymus and activation-regulated chemokine (TARC/CCL17) relates to reactivation of human herpesvirus 6 in drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS)[J]. Br J Dermatol, 2014, 171(2): 425-427.
[10] TANG XY, LI Y, MA K, et al.Clinical analysis of drug-induced hypersensitivity syndrome in 26 children[J]. Chin J Derma Venereol(中国皮肤性病学杂志), 2019, 33(6): 679-693.
[11] HUA X, LIU HJ, ZHANG M, et al.Clinical analysis of 55 cases of drug reaction with eosinophilia and systemic symptoms[J].Chin J Derma Venereol(中国皮肤性病学杂志), 2015, 29(3): 262-264.
[12] SHIOHARA T, KANO Y.Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and manag-ement[J]. Expert Opin Drug Saf, 2017, 16(2): 139-147.
[13] KARDAUN SH, SIDOROFF A, VALEYRIE-ALLANORE L, et al.Variability inthec-linical pattern of cutaneous side effects of drugs with systemic symptoms: does a DRESS syndrome really exist?[J]. Br J Dermatol, 2007, 156(3) : 609-611.
[14] CRIADO PR, CRIADO RF, AVANCINI JM, et al.Drug reaction with eosinophilia and systemic symptoms (DRESS) / drug-induced hypersensitivity syndrome (DIHS): a review of current concepts[J]. An Bras Dermatol, 2012, 87(3) : 435-449.
[15] CHIOU CC, YANG LC, HUNG SI, et al.Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan[J]. J Eur A Card Dermatol Venereol, 2008, 22(9) : 1044-1049.
[16] MARTINEZ-RODRIGUEZ JE, BARRIGA FJ, SANTAMARIA J, et al.Noncon-vulsive status epflepticus associated with cephalosporins in patients with renal failure[J]. Am J Med, 2001, 111(2): l15-l19.
[17] YANG J, LIU LH, YANG H.Two cases of epilepsy form seizure caused by cefoperazone sodium and sulbactam sodium[J]. Journal of Clinical Pharmacotherapy(临床药物治疗杂志), 2017, 15(12): 49-50, 54.
[18] ZHANG JA, WANG HL, GUO JP, et al.One case of epilepsy induced by Cefoperazone/sulbactam[J]. China Pharmacist(中国药师), 2011, 14(11): 1664-1665.
[19] YANG JZ, XIONG JH, CHEN DW, et al.Analysis of influence factors of adverse reactions of the nervous ssystem caused by cefoperazone/ sulbactam[J]. Chin J Pharmacoepidemiol(药物流行病学杂志), 2016, 25(9): 563-567.
[20] WALLACE KL.Antibiotic-induced convulsions[J]. Crit Care Clin, 1997, 13(4): 741-762.
[21] FAN QE, YE F, LYU GH, et al.One case of epilepsy induced by cefoperazone and sulbactam[J]. China Pharmacist(中国药师), 2018, 21(10): 1819-1820.
[22] SCHÄFER H, NABER K, ADAM D. Hemostasis disturbance caused by cephalosporins with an N-methylthiotetrazole side chain: a randomized pilot study[J]. Arzneimittel-forschung, 1989, 39(9): 1156-1162.
[23] SHEARER MJ, BECHTOLD H, ANDRASSY K, et al.Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status[J]. J Clin Pharmacol, 1988, 28(1): 88-95.
[24] ZHANG LL, MA LY, CHEN CY, et al.Case report analysis of thrombocytopenia induced by cefoperazone sodium/sulbactam sodium in patient with chronic kidney disease[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2019, 35(11): 1186-1188.
[25] SHAO XM, YE HM, QIU XS.Practice of Neonatology(实用新生儿学)[M]. 4th ed.Beijing: People's Medical Publishing House, 2016: 633.
[26] Pediatrics Group of Microecology Branch of Chinese Preventive Medicine Association. Evidence-based guidelines to the clinical application of probiotics in pediatrics[J]. Chinese Journal of Practical Pediatrics(中国实用儿科杂志), 2017, 32(32): 81-90.